Rules 4.7.3 and 4.10.3 ASX Listing Rules Appendix 4G (current at 17/7/2020) Page 1 Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Name of entity ARGENT BIOPHARMA LTD ABN/ARBN Financial year ended: 30 116 800 269 30 June...
Appendix 4G and Corporate Governance Statement
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Argent Biopharma
- FDA-CVM Establish INAD File for CannEpil Veterinary Program
- Proposed issue of securities - RGT
- $250,000 in Funding Received under Financing Facility
- US Veterinary Development Programme for CannEpil Commences
- Notification of cessation of securities - RGT
Later from Argent Biopharma
- Appendix 4E and 2026 Annual Report
- Argent Signs NLC Licence to Expand Antiviral Portfolio
- Execution of Loan Facility Agreement
- Application for quotation of securities - RGT
- Strategic Focus on Immune Modulation and Longevity
Follow Argent Biopharma into a list and get an email when it puts out news.
Follow Argent Biopharma